Molecular therapeutics in breast cancer
1 – 10 of 28
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance
(
- Contribution to journal › Article
-
Mark
Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
(
- Contribution to journal › Article
- 2024
-
Mark
Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer : results from a population-based cohort
2024) In Breast Cancer Research and Treatment(
- Contribution to journal › Article
-
Mark
The analytical and clinical validity of AI algorithms to score TILs in TNBC : can we use different machine learning models interchangeably?
(
- Contribution to journal › Article
-
Mark
Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer
(
- Contribution to journal › Article
- 2023
-
Mark
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
(
- Contribution to journal › Article
-
Mark
Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer
(
- Contribution to journal › Article
-
Mark
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer : a multidisciplinary expert consensus
(
- Contribution to journal › Scientific review
-
Mark
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
(
- Contribution to journal › Article
- 2022
-
Mark
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
(
- Contribution to journal › Article